2443491-73-2
2443491-73-2
Chemical Structure
(7S)-Nivegacetor
Synonym(s): (7S)-RG6289
- CAS No.: 2443491-73-2
- Formula:C23H25F2N7O2
- Molecular Weight:469.49
InChIKey: YYYGNCPNCFDABE-AAJFEFCHSA-N
SMILES: [H][C@@]1(CC2)CN(C3=CN=NC(OC)=C3)C[C@@]2([H])[C@@H]1NC4=NN(CC[C@@H]5OC6=CC(F)=CC(F)=C6)C5=N4
Biological Activity: (7S)-Nivegacetor ((7S)-RG6289) is an isomer of Nivegacetor (HY-159836). Nivegacetor (RG6289) is a potent and selective γ-secretase modulator. Nivegacetor reduces Aβ42 production and can be used in Alzheimer's disease research[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(7S)-Nivegacetor | (7S)-Nivegacetor ((7S)-RG6289) is an isomer of Nivegacetor (HY-159836). Nivegacetor (RG6289) is a potent and selective γ-secretase modulator. Nivegacetor reduces Aβ42 production and can be used in Alzheimer's disease research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Tariot P N, et al. Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial[J]. The Lancet Neurology, 2026, 25(2): 147-159. [Content Brief]
